Excited to launch the first edition of B.I.T. an event totally dedicated to translational research in breast cancer!! Join me and a stellar international faculty in Padova, 29-30th april.
delphiecm.it/evento/b-i-t-b…

Thank you Lorenzo Gerratana for your vision! This was a highly interactive meeting, honoured to have contributed.

I have been waiting for almost 40 years… #grilloparlante #vintagetoys #millenial #newchallenges

What does it mean being married with an artist. Part 2. Trailer “4:04”short animation movie. #animation #illustration #comics #art instagram.com/reel/C1cYKH9N4…

What does it mean being married with an artist 👨🏻‍🎨👇🏻 #illustration #comics #art #animation instagram marcomaselli_art

ERlow = ERneg BC from molecular and immune perspective. Come to visit our poster P01-03-09. Find us in the “Triple Negative” poster row: a sign that times are finally mature for a change? Gaia Griguolo Federica Miglietta Università di Padova IOV - Istituto Oncologico Veneto #SABCS23 OncoAlert

Nuova tappa per Next Oncology - Supporting Oncology through Innovation.
Un simposio 'Le frontiere dell' oncologia: focus ADC' sulle opzioni terapeutiche basate su anticorpi monoclonali farmaco-coniugati.
P. Pronzato Carmine De Angelis Maria Vittoria Dieci Matteo Lambertini, MD PhD Sara Lonardi Francesco

Domani 11/11-Congresso AIOM
WE ARE NEXT–Le frontiere dell’oncologia: focus ADC
Gli anticorpi monoclonali farmaco-coniugati come promettente opzione terapeutica.
Con P. Pronzato, Carmine De Angelis Maria Vittoria Dieci Matteo Lambertini, MD PhD, Sara Lonardi Francesco.
Iscrizioni: overgroup.eu/evento/we-are-…

In HR+HER2- early breast cancer, high genomic risk tumors by OncotypeDX present higher levels of TILs (more than 10%) ! -> potential clinical implications?
Great minioral presentation today by Federica Miglietta of our group at #ESMO23 !
#bcsm Maria Vittoria Dieci Università di Padova IOV - Istituto Oncologico Veneto

🧬Molecular heterogeneity of HER2+ early BC influences the pattern of metastatic relapse

🩻Potential implications for follow up and clinical trial design

Check out our new JNCI paper 👇🏻
Università di Padova Aleix Prat #PrecisionOncology Gaia Griguolo Federica Miglietta IOV - Istituto Oncologico Veneto

academic.oup.com/jnci/advance-a…

Finally out on Journal of Clinical Oncology the 10-Year update of the ShortHER trial: proud and honored to be part of this relevant work
Maria Vittoria Dieci

ascopubs.org/doi/full/10.12…

Idioti, hanno cercato di distruggere un drago col fuoco!
Drago Vaia in fiamme DEVE rinascere gofund.me/2238ee8d

Super proud that our work on a prognostic model for OS based on RCB + RD-TILs after NAT in HER2+ BC is finally out on Clinical Cancer Research!!
⬆️ TILs on RD —> worse OS
⬆️ RCB-TIL scores —> worse OS

Maria Vittoria Dieci Gaia Griguolo Michele Bottosso

aacrjournals.org/clincancerres/…

#ESMOBreast23
Conclusions from the excellent translational research highlights overview by Christine Desmedt⁩👏 ⁦ESMO - Eur. Oncology⁩ ⁦OncoAlert⁩ #bcsm ⁦Lobular Breast Cancer Alliance⁩ ⁦KarenVanBaelen⁩ ⁦Hava Izci⁩

Tumor immune microenvironment in ER negative/HER2neg compared to ER low( 1-9%).
Control group was tumors with intermediate ER expression
📌 no diff in TILS, CD8,PDL-1 between TNBC and ER low/HER2 neg.
But diff from Intermediate ER expression. #esmobreast23 OncoAlert

❓should ERlow/HER2neg BC be considered as TNBC?

👉🏻 don’t miss our #ESMOBreast23 presentations:

📍Today: 1MO by Davide Massa comparing the immune microenvironment of ER 0% vs ERlow/HER2neg BC

📍Tomorrow: 211P by Federica Miglietta on ERlow MBC

Università di Padova Carmen Criscitiello Gaia Griguolo

19th Meet the Professor. International Breast Cancer Course. Padova.

Registration now open!

link: bit.ly/3HuZtBD

Check out the outstanding program! Tomás Pascual Mafalda Oliveira Gaia Griguolo G Curigliano MD PhD Hope Rugo Sandra